This article is more than 5 years old. Information may no longer be current.
Ranibizumab 0.5 mg effectively manages pigment epithelial detachment
Click Here to Manage Email Alerts
Monthly or as-needed 0.5-mg injections of ranibizumab were effective in treating pigment epithelial detachment associated with neovascular age-related macular degeneration, according to a post hoc analysis of the HARBOR study.
Visual acuity improved regardless of the status or height of pigment epithelial detachment (PED) at baseline. In addition, a 2-mg dose of Lucentis (ranibizumab, Genentech) led to a higher rate of PED resolution but offered no additional improvement in visual acuity.
The analysis included 1,097 patients, of whom 598 had PED at study baseline. In those who had PED, 154 patients received 0.5 mg ranibizumab monthly, 146 patients received 0.5 mg ranibizumab as needed, 158 patients received 2 mg ranibizumab monthly, and 140 patients received 2 mg ranibizumab as needed.
At 24 months, monthly ranibizumab 0.5 mg improved best corrected visual acuity by nine letters in patients with PED at baseline and 11.3 letters in those without PED at baseline. As-needed ranibizumab 0.5 mg improved BCVA by 8.4 letters in patients with PED at baseline and 7.9 letters in those without PED at baseline.
Monthly ranibizumab 2 mg improved BCVA by 7.1 letters in patients with PED at baseline and 11.1 letters in those without PED at baseline. As-needed ranibizumab 2 mg improved BCVA by 7.2 letters in patients with PED at baseline and 8.8 letters in those without PED at baseline.
PED resolved completely at 24 months in 53.2% of patients in the 0.5 mg monthly group, 44.5% of patients in the 0.5 mg as-needed group, 70.4% of patients in the 2 mg monthly group and 57.3% of patients in the 2 mg as-needed group. – by Matt Hasson
Disclosure: Sarraf reports he is a consultant for Optovue and Genentech and receives financial support from Allergan, Genentech, Regeneron and Optovue. See the study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts